Oppenheimer reissued their buy rating on shares of ConforMIS (NASDAQ:CFMS) in a report released on Thursday morning.
A number of other research analysts have also weighed in on CFMS. Zacks Investment Research raised shares of ConforMIS from a hold rating to a buy rating and set a $1.50 price target on the stock in a research report on Tuesday. Canaccord Genuity reissued a hold rating on shares of ConforMIS in a research report on Monday, March 12th. Cowen began coverage on shares of ConforMIS in a research report on Wednesday, February 21st. They set an outperform rating and a $4.00 price target on the stock. JPMorgan Chase & Co. lowered shares of ConforMIS from a neutral rating to an underweight rating in a research report on Tuesday, January 2nd. Finally, BTIG Research raised shares of ConforMIS from a neutral rating to a buy rating and set a $4.00 price target on the stock in a research report on Wednesday, December 20th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $4.29.
Shares of ConforMIS stock traded down $0.03 during midday trading on Thursday, hitting $1.41. 84,470 shares of the stock were exchanged, compared to its average volume of 664,759. The firm has a market capitalization of $88.22, a PE ratio of -1.15 and a beta of 1.22. ConforMIS has a 52-week low of $1.15 and a 52-week high of $5.98. The company has a debt-to-equity ratio of 0.64, a current ratio of 5.41 and a quick ratio of 4.70.
ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 85.24%. The company had revenue of $20.80 million for the quarter, compared to analyst estimates of $20.07 million. During the same period last year, the firm earned ($0.37) earnings per share. The firm’s revenue was down 4.1% on a year-over-year basis. research analysts forecast that ConforMIS will post -0.86 EPS for the current year.
A number of hedge funds have recently made changes to their positions in CFMS. Northern Trust Corp raised its position in ConforMIS by 15.2% in the second quarter. Northern Trust Corp now owns 454,468 shares of the medical instruments supplier’s stock worth $1,950,000 after acquiring an additional 60,034 shares during the period. Ark Investment Management LLC raised its position in ConforMIS by 208.5% in the second quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock worth $825,000 after acquiring an additional 130,009 shares during the period. State Street Corp raised its position in ConforMIS by 1.5% in the second quarter. State Street Corp now owns 594,583 shares of the medical instruments supplier’s stock worth $2,550,000 after acquiring an additional 8,693 shares during the period. The Manufacturers Life Insurance Company raised its position in ConforMIS by 21.4% in the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after acquiring an additional 6,535 shares during the period. Finally, Granite Investment Partners LLC bought a new stake in ConforMIS in the third quarter worth about $859,000. 22.97% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/23/conformiss-cfms-buy-rating-reiterated-at-oppenheimer.html.
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.